Cargando…

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

BACKGROUND: Clinical trials have shown the cardiovascular protective effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the association between SGLT2 inhibitors and the risk of arrhythmias. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hung-Yi, Huang, Jing-Yang, Siao, Wun-Zhih, Jong, Gwo-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275510/ https://www.ncbi.nlm.nih.gov/pubmed/32503541 http://dx.doi.org/10.1186/s12933-020-01048-x

Ejemplares similares

The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study
por: Siao, Wun-Zhih, et al.
Publicado: (2022)

Increased risk of valvular heart disease in patients with ankylosing spondylitis: a nationwide population-based longitudinal cohort study
por: Siao, Wun-Zhih, et al.
Publicado: (2021)

The association between SGLT2 inhibitors and new-onset acute coronary syndrome in the elderly: a population-based longitudinal cohort study
por: Lin, Tsung-Kun, et al.
Publicado: (2023)

Case Report: A Rare Manifestation of Pulmonary Arterial Hypertension in Ankylosing Spondylitis
por: Yang, Tsung-Yuan, et al.
Publicado: (2022)

Risk of peripheral artery disease and stroke in migraineurs with or without aura: a nationwide population-based cohort study
por: Siao, Wun-Zhih, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

High exposure to statins decrease the risk of new-onset dementia: A nationwide population-based longitudinal cohort study
por: Chang, Chih-Feng, et al.
Publicado: (2019)

Diabetes Mellitus and Heart Failure
por: Siao, Wun-Zhih, et al.
Publicado: (2022)

Long-term effect of statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study
por: Lin, Tsung-Kun, et al.
Publicado: (2018)

High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study
por: Lin, Tsung-Kun, et al.
Publicado: (2018)

Antihypertensive Drug Use and New-Onset Diabetes in Female Patients with Coronary Artery Disease: A Population-based Longitudinal Cohort Study
por: Liou, Yi-Sheng, et al.
Publicado: (2015)

Long-term outcomes of dialysis in patients with chronic kidney disease and new-onset atrial fibrillation: A population-based cohort study
por: Hung, Tung-Wei, et al.
Publicado: (2019)

Long-term Effects of Antihypertensive Drug Use and New-onset Osteoporotic Fracture in Elderly Patients: A Population-based Longitudinal Cohort Study
por: Chen, Hung-Yi, et al.
Publicado: (2016)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
por: Lin, Chu, et al.
Publicado: (2021)

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
por: Shao, Shih-Chieh, et al.
Publicado: (2021)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study
por: Kim, Yun Gi, et al.
Publicado: (2019)

Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes
por: Yoneda, Zachary T., et al.
Publicado: (2021)

A Retrospective Longitudinal Cohort Study of Antihypertensive Drug Use and New-Onset Diabetes in Taiwanese Patients
por: Huang, Ching-Ya, et al.
Publicado: (2013)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Association of Arrhythmia in Patients with Cervical Spondylosis: A Nationwide Population-Based Cohort Study
por: Lin, Shih-Yi, et al.
Publicado: (2018)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study
por: Zareini, B., et al.
Publicado: (2019)

Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes
por: Yoneda, Zachary T., et al.
Publicado: (2022)

Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
por: Seong, Jong-Mi, et al.
Publicado: (2020)

Weight change and mortality and cardiovascular outcomes in patients with new-onset diabetes mellitus: a nationwide cohort study
por: Kim, Mee Kyoung, et al.
Publicado: (2019)

Gender- and age-related differences of statin use on incident dementia in patients with rheumatoid arthritis: a Nationwide population-based cohort study
por: Lin, Tsung-Kun, et al.
Publicado: (2021)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
por: Aroor, Annayya R., et al.
Publicado: (2018)

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
por: McGuire, Darren K., et al.
Publicado: (2020)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
por: Hwang, In-Chang, et al.
Publicado: (2020)

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
por: Smidt, Lisanne C. A., et al.
Publicado: (2021)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

Correction to: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta‑analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study
por: Lin, Tsung-Kun, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
por: Chang, Chia-Yu, et al.
Publicado: (2017)

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials
por: Cherney, David Z. I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cq3d6aeatgmfkj9llfj4gtnnpk